[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"inflammatory-bowel-disease-crohn39s-disease-and-ulcerative-colitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:inflammatory-bowel-disease-crohn39s-disease-and-ulcerative-colitis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,51,75,104,125,150,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":4},"100639369","phase-2-modafinil-for-debilitating-fatigue-in-quiescent-inflammatory-bowel-disease-modifi-ibd-trial-100639369",false,"NCT07582458","Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease MODIFI-IBD Trial)","Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease: a Multicentre,Randomised, Double-blind, Placebo-controlled, Clinical Trial (MODIFI-IBD Trial)","MODIFI-IBD","Inclusion Criteria:\n\n* Willing and able to provide signed informed consent at the screening visit as well as comply with all study visits and requirements through the end of the study\n* Age between 18 to 75 years at screening.\n* ≥1 year diagnosis of IBD, based on a combination of clinical, endoscopic, histologic and radiologic criteria\n* Chronic fatigue for at least six months\n* Severe fatigue as confirmed with a score of ≥11 on section I of the IBD-F\n* Clinically quiescent IBD with a Harvey Bradshaw Index (HBI) \\\u003C5 for CD patients or a Simple Colitis Clinical Activity Index (SCCAI) ≤2 for patients with UC or IBD-unclassified\n* Faecal calprotectin \\\u003C250 µg\u002Fg\n* Stable IBD medication for ≥3 months before screening visit and no change in IBD medication planned for ≥3 months\n\nExclusion Criteria:\n\n* Contraindications for the use of modafinil, such as:\n\n  * Uncontrolled hypertension\n  * Cardiac arrhythmia\n  * A history of left ventricular hypertrophy or cor pulmonale, and in patients with mitral valve prolapse who have previously developed mitral valve prolapse syn-drome during treatment with central nervous system stimulants\n  * Patients with hereditary galactose intolerance, lactase deficiency, glucose-galactose malabsorption\n* Patients using medication which interacts clinically significant with modafinil, see section 3.3 'Mechanism of action \\& Drug class'\n* Patients using pharmacological agents with similar effects to modafinil, like central nerv-ous system (CNS) stimulants or other wakefulness-promoting drugs such as methylphenidate and amphetamines\n* Surgery before or during study period that impacts ability to participate in this study, per investigator judgement\n* Participation in another intervention study (excl. registries and post marketing studies)\n* Pregnancy or nursing at the moment of screening or planned pregnancy within two months after last dose\n* People with a diagnosis of drug or alcohol dependence syndrome will be excluded\n* Comorbidities or confirmed diagnoses known to cause fatigue, which may influence study outcomes, including but not limited to:\n\n  * Anaemia (Hb \\\u003C7.0 mmol\u002Fl for women and \\\u003C8.0 mmol\u002Fl for men) and which is judged as clinically significant by the investigator\n  * Folate deficiency (\\\u003C6.0 nmol\u002Fl)\n  * Iron deficiency (ferritin \\\u003C20 g\u002Fl for women and \\\u003C25 g\u002FL for men)\n  * Vitamin B12 deficiency (\\\u003C148 pmol\u002Fl)\n  * Liver insufficiency defined by an ALT or AST \\>2x ULN or total bilirubin \\> 2 mg\u002FdL\n  * Renal insufficiency defined by an estimated glomerular filtration rate \\\u003C 45 mL\u002Fmin, calculated using the Chronic Kidney Disease-Epidemiology Collaboration equation and\u002For a serum creatinine \\>178 μmol\u002FL (2mg\u002FdL)\n  * Auto-immune disorders such as primary sclerosing cholangitis, rheumatoid ar-thritis, systemic lupus erythematosus or coeliac disease\n  * Uncontrolled or recently diagnosed depression\n  * Active suicidal ideation\n  * Bipolar disorder\n  * Schizophrenia or other psychotic disorders\n  * Other psychiatric disorders that may interfere with the study as judged by the investigators\n  * History or current anxiety or sleep disorders\n  * Substance dependence disorders (e.g. alcohol, cannabis, drugs)\n  * Evidence, history, or suspicion of infectious diseases that may interfere with the study as judged by the investigators\n  * Active Epstein-Barr virus or cytomegalovirus infection\n  * Endocrinological disorders such as uncontrolled diabetes mellitus, untreated hy-pothyroidism, hypoadrenalism or hypogonadism\n  * Neurological disorders such as multiple sclerosis, dementia, Parkinson's disease or myasthenia gravis\n  * Heart failure\n  * Chronic obstructive pulmonary disease\n  * Obstructive sleep apnoea\n  * Active malignancy (exception of malignancies adequately treated with resection for non-metastatic basal cell carcinoma)\n  * Long\u002Fpost-COVID\n* Patients who are not able to complete the Dutch questionnaires in an online form\n* Has a clinically significant concurrent disease or relevant laboratory abnormality or a history of illness or medical condition that in the investigator's opinion could confound the study results or increase the participant's risk by taking part in the study","ALL","18 Years","75 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE2","PHASE3","The goal of this clinical trial is to learn if modafinil can treat severe fatigue in adults aged 18 to 75 years with quiescent inflammatory bowel disease (IBD). The main questions it aims to answer are:\n\nDoes modafinil reduce fatigue more effectively than placebo, as measured by the mean difference in section I of the IBD-F questionnaire at week 8? Is modafinil safe and well tolerated in patients with quiescent IBD and severe fatigue?\n\nResearchers will compare modafinil to placebo to see if modafinil improves fatigue outcomes.\n\nParticipants will:\n\nattend one screening visit including assessment of disease activity, blood tests, stool testing, and an ECG; take modafinil or placebo for 8 weeks, starting at 100 mg daily with possible dose increases based on response and tolerability; complete online questionnaires at baseline, week 4, week 8, and week 12 about fatigue, quality of life, sleep, mood, and work productivity; be contacted regularly during the treatment period to discuss effect and side effects of the study medication; complete an online effort-based decision-making task at baseline and week 8.",[29,30],"Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)","Chronic Fatigue",[32,33,34,35,36,37,38],"Modafinil","Inflammatory bowel disease","Crohn","Colitis","Fatigue","Remission","Pharmacological","NOT_YET_RECRUITING","2026-05-19",{"date":42,"type":43},"2026-05-22","ACTUAL",{"date":45,"type":22},"2026-06-01",{"date":47,"type":22},"2027-06",{"name":49,"class":50},"Radboud University Medical Center","OTHER",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100639884","research-on-the-whole-process-of-ai-intelligent-management-system-for-the-diagnosis-and-treatment-of-inflammatory-bowel-diseases-100639884","NCT07590271","Research on the Whole Process of AI Intelligent Management System for the Diagnosis and Treatment of Inflammatory Bowel Diseases","Inclusion Criteria:\n\nInclusion criteria for the IBD group:\n\nPatients diagnosed with IBD (K50.00 to K51.919) within the specified time interval.\n\nInclusion criteria for the non-IBD group:\n\nPatients never diagnosed with IBD (K50.00 to K51.919) within the specified time interval.\n\nExclusion Criteria:\n\nPatients not within the specified time interval Deceased patients\n\nExclusion criteria for the non-IBD group:\n\nPatients not within the specified time interval Deceased patients Patients with fewer than 5 hospital visits",{"count":58,"type":22},4500,"OBSERVATIONAL","Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic immune-mediated disorder requiring long-term management. Clinically, IBD may involve recurrent intestinal inflammation, ulcer formation, and complications such as strictures and fistulas. The etiology of IBD is associated with immune dysregulation, gut microbiome imbalance, and genetic susceptibility. Its clinical manifestations are heterogeneous; early symptoms such as abdominal pain, diarrhea, weight loss, hematochezia, or anemia often resemble gastroenteritis, irritable bowel syndrome, or infectious enterocolitis, leading to misdiagnosis and delayed diagnosis. According to international studies, the interval between initial symptom onset and confirmed diagnosis can range from several months to years, during which untreated disease progression increases the risks of hospitalization, surgery, bowel strictures, and fistulizing complications, resulting in significant impacts on patient quality of life.\n\nThis study adopts a retrospective design, analyzing our hospital's electronic medical record data from 2023 to 2025.The objective is to evaluate the performance and feasibility of an artificial intelligence (AI) model-developed and incorporating natural language processing (NLP) and phenotypic recognition algorithms-in supporting early identification and diagnosis of IBD. The model has been validated in multiple European healthcare systems and is capable of recognizing high-risk phenotypic clusters from large-scale structured and unstructured medical data. This study represents the first application of this AI technology in the Taiwanese IBD population. All data processing will occur within a de-identified and secure computing environment to ensure data privacy and information security.\n\nThe study will compare AI-generated diagnostic suggestions derived from medical records with actual clinical diagnoses to assess consistency and accuracy. The model's performance across different clinical characteristics, disease severity levels, and stages of illness will also be examined. In addition, statistical metrics such as precision and recall will be used to generate PRC curves for determining the optimal diagnostic threshold. The outcomes of this study are expected to validate the potential of AI technology in facilitating early recognition, accelerating diagnosis, and supporting clinical decision-making for IBD. The findings will provide essential data for developing localized AI models for IBD, ultimately enhancing diagnostic efficiency, shortening the diagnostic timeline, and improving long-term patient outcomes and quality of life.\n\nObjective 1：To retrospectively analyze the clinical characteristics and diagnostic pathways of patients with IBD (CD\u002FUC).\n\nObjective 2：To evaluate the performance of the AI model in identifying and providing diagnostic suggestions for high-risk IBD cases.\n\nObjective 3：To compare the accuracy and consistency between AI-generated diagnostic suggestions and actual clinical diagnoses.",[29,62,63,64,65],"Crohn's Disease (CD)","Ulcerative Colitis (UC)","Artificial Intelligence (AI)","Natural Language Processing (NLP)","2026-05-11",{"date":68,"type":43},"2026-05-15",{"date":45,"type":22},{"date":71,"type":22},"2027-12-31",{"name":73,"class":50},"Taichung Veterans General Hospital",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":103},"100578378","alpco-calprotectin-clia-assay---measurement-of-calprotectin-levels-in-human-stool-100578378","NCT06810518","ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool","Inclusion criteria:\n\n* Male or female, ≥22 years of age (adults)\n* Suspected inflammatory bowel disease or irritable bowel syndrome with symptoms such as abdominal pain, diarrhea, altered appetite, weight loss, or anemia\n* Able to provide a sample according to the sampling protocol within 72-24 hours prior to the scheduled diagnostic endoscopy or 3-30 days after the colonoscopy.\n* Able to understand the study and the tasks required and sign the ICF\n\nExclusion criteria:\n\n* Unable or unwilling to provide a stool specimen\n* Known active intestinal cancer or in remission with abnormal levels (per physician assessment)\n* Known active intestinal infection or history of treated intestinal infection with persistent abnormal levels (per physician assessment)\n* IBD patients receiving chemotherapy or systemic immunosuppressive drugs without completing an 8-week washout period\n* IBD patients who have previously diagnosed IBD managed with immunomodulators, 5-ASA or biologic therapies without completing an 8-week washout period for biologics and immunomodulators or 4 weeks for 5-ASA\n* IBD patients who have previously been diagnosed with IBD and have undergone a surgical resection or diversion procedure.\n* Known upper Gl disease such as esophagitis or gastritis that might influence the study test's ability to detect intestinal inflammatory disease\n* Have taken NSAIDS (including aspirin) on 7 or more days during the 2 weeks before providing the sample\n* Samples are not collected according to sampling protocol.\n* Any condition that in the opinion of the investigator should preclude participation in the study.\n\nUsing an IRB approved consent form, all study participants will be advised of study requirements and potential risks associated with study participation.",true,"22 Years",{"count":84,"type":22},220,"The ALPCO Calprotectin CLIA is an in vitro diagnostic test intended to quantitatively measure concentrations of fecal calprotectin in human stool samples. Calprotectin is a protein biomarker of mucosal inflammation. Measurement of calprotectin can aid in the diagnosis of Inflammatory Bowel Diseases (IBD), specifically Crohn's Disease (CD) and Ulcerative Colitis (UC), as well as aid in the differentiation of IBD from Irritable Bowel Syndrome (IBS) when used in conjunction with other diagnostic testing and the total clinical picture. The goal of the study is to generate data to support positive and negative predictive value of the ALPCO Calprotectin assay in patients with signs and symptoms of IBS or IBD.",[29,87],"Inflammatory Bowel Syndrome",[89,90,91],"calprotectin","IBD","IBS","RECRUITING","2026-04-27",{"date":95,"type":43},"2026-04-28",{"date":97,"type":43},"2025-03-25",{"date":99,"type":22},"2026-12-31",{"name":101,"class":102},"American Laboratory Products Company","INDUSTRY",3,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":81,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":74},"100617094","study-on-the-use-of-traditional-chinese-medicine-diagnostic-tools-to-assist-in-identifying-the-clinical-characteristics-of-inflammatory-bowel-disease-and-research-on-metabolic-plastids-of-tongue-coating-100617094","NCT07314151","Study on the Use of Traditional Chinese Medicine Diagnostic Tools to Assist in Identifying the Clinical Characteristics of Inflammatory Bowel Disease and Research on Metabolic Plastids of Tongue Coating","Inclusion Criteria:\n\n* Adult patients aged 18 years or older who are able to provide informed consent and comply with the study procedures.\n* Experimental group: Patients with a primary diagnosis of Crohn's disease or ulcerative colitis, defined by ICD-10-CM codes K50-K51.\n* Control group: Individuals without inflammatory bowel disease and without significant gastrointestinal symptoms.\n\nExclusion Criteria:\n\n* Individuals who are unable to provide informed consent or unable to comply with study procedures or questionnaires.\n* Individuals who have undergone major surgery or received chemotherapy or radiotherapy within the past month.\n* Pregnant women.\n* Individuals deemed unsuitable for participation in this study by the attending physician.\n* Control group exclusions:\n\n  * Individuals with any diagnosed psychiatric disorder.\n  * Individuals with any major gastrointestinal disease, such as gastrointestinal malignancy.",{"count":111,"type":22},200,"This study will be conducted at the outpatient clinic of China Medical University hospital. It is expected to enroll two groups of 30 subjects, including the experimental group must meet the clinical diagnosis of IBD, and the control group without IBD and have no obvious gastrointestinal symptoms . This proje ct uses modern TCM diagnostic tools, such as tongue diagnosis instrument, auscul tation instrument, TCM constitution questionnaire, and pulse diagnosis instrument to establish the comparison of physiological and biochemical indicators such as TCM phenotype and laboratory tests data in patients with IBD. Besides, another purpose of this project is to analyze the tongue coating metabolites of patients with IBD by mass spectrometry, and to establish a research model of tongue coating an d metabolomics for patien ts with IBD and the prognosis analysis of acute and remission phases.",[29],[115],"inflammatory bowel disease, Crohn's disease, ulcerative colitis, gut brain axis, Traditional Chinese medicine (TCM) diagnosis, Tongue diagnosis, Metabolomics","2025-12-23",{"date":118,"type":43},"2026-01-02",{"date":120,"type":43},"2024-02-15",{"date":122,"type":22},"2026-07-31",{"name":124,"class":50},"China Medical University Hospital",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":74},"100615426","prevalence-of-helicobacter-pylori-on-patients-with-chronic-inflammatory-bowel-disease-ibd-at-the-chu-of-guadeloupe-100615426","NCT07292454","Prevalence of Helicobacter Pylori on Patients With Chronic Inflammatory Bowel Disease (IBD) at the CHU of Guadeloupe","HP-MICI","Inclusion Criteria:\n\nPatients over 18 years old Patients with IBD from the CHU of Guadeloupe Patients benefiting from an investigation of H. pylori infection through gastric biopsies and\u002For serology at the time of diagnosis of IBD Patients affiliated to the French social security system Free informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research)\n\nExclusion Criteria:\n\nPatients of less than18 years Patients having not given their writing informed consent",{"count":133,"type":22},100,"Clinical and experimental data suggest that dysbiosis may play a pivotal role in the pathogenesis of intestinal bowel disease (IBD). However, to the best of our knowledge, the composition of gastric and of intestinal microbiome has never been investigated in a population with IBD according to the presence\u002Fabsence of Helicobacter pylori (H. pylori) in the stomach.",[136,29],"HELICOBACTER PYLORI INFECTIONS",[138,139,136,140],"intestinal microbioma","gastric microbioma","Inflammatory Bowel Disease","2025-12-05",{"date":143,"type":43},"2025-12-18",{"date":145,"type":22},"2025-12-15",{"date":147,"type":22},"2026-12-15",{"name":149,"class":50},"Centre Hospitalier Universitaire de la Guadeloupe",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":158,"targetDuration":160,"studyType":59,"phases":4,"briefSummary":154,"conditions":161,"keywords":165,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":74},"100603116","molecular-inflammation-board-at-the-center-for-personalized-medicine-100603116","NCT07132333","Molecular Inflammation Board at the Center for Personalized Medicine","The Molecular Inflammation Board at the Centers for Personalized Medicine at the University Hospitals of Freiburg, Heidelberg, Tübingen and Ulm - A Multicenter Prospective Observational Study","MEB@ZPM","Inclusion Criteria:\n\n* Chronic inflammatory disorder (PsO, PsA, SpA, IBD)\n* Given informed consent\n* 18 years of age\n\nExclusion Criteria:\n\n* No capacity to consent",{"count":159,"type":22},3000,"14 Months",[162,163,29,164],"Psoriasis (PsO)","Psoriasis Arthritis","Spondylarthropathies",[166,167],"chronic inflammatory diseases","personalized medicine","2025-08-19",{"date":170,"type":43},"2025-08-20",{"date":172,"type":43},"2022-11-16",{"date":174,"type":22},"2032-11",{"name":176,"class":50},"University Hospital Tuebingen",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":4},"100594517","spiritual-needs-of-european-patients-with-inflammatory-bowel-disease-and-their-caregivers-100594517","NCT07020481","Spiritual Needs of European Patients With Inflammatory Bowel Disease and Their Caregivers","Spiritual Needs of Patients With Inflammatory Bowel Disease and Their Caregivers: a European Cross-sectional Nursing Study","Spirit@IBD","Inclusion Criteria:\n\n* adolescents and adults of all ages clinically diagnosed with CD, UC, or any other form of IBD (such as indeterminate colitis or IBD unclassified).",{"count":186,"type":22},1000,"A European-wide cross-sectional non-interventional study, initiated by a pilot study in Italy, will be conducted. The first phase of the pilot study is a 6-step translation, adaptation, and validation of the extended version of the Spiritual Needs Questionnaire (SpNQ-EV) and the Interpretation of Illness Questionnaire (IIQ) adopting the methodology \\[3\\] described in figure 1. To ensure they are both valid and user-friendly, the Thinking Out Loud (TOL) technique (think-aloud method) will pre-test their self-administration and provide fine tuning of the secondary objectives of the study. TOL involves participants verbalizing their thoughts while completing the questionnaires, allowing to capture real-time insights into their understanding, interpretation, and potential challenges with questionnaires' items. The second phase will consist of an anonymous e-survey consisting of the six questionnaires described in table 1 including the translated and validated SPNQ-EV and IIQ developed in phase 1. The European study will employ a multilingual anonymous e-survey developed to ensure accessibility in participants' native languages, eventually preceded by country-based pilot studies. Eligible participants include adolescents and adults with IBD, as well as their caregivers, recruited via nurses and patient associations.",[29],"2025-06-12",{"date":191,"type":43},"2025-06-13",{"date":193,"type":22},"2025-09",{"date":195,"type":22},"2025-12-31",{"name":197,"class":50},"University of Padova"]